지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 623 - 631 (9page)
이용수
초록· 키워드
오류제보하기
Purpose Epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for approximately 4% of all EGFRmutations. Given the rarity of this mutation, its clinical outcomes are not fully established. Materials and Methods Between 2009 and 2017, non-small cell lung cancer (NSCLC) patients who showed an exon 20 insertion were retrospectively reviewed for clinical characteristics and outcomes, including responses to chemotherapy (CTx) or targeted therapy. Results Of 3,539 NSCLC patients who harbored an activating EGFR mutation, 56 (1.6%) had an exon 20 insertion. Of the advanced NSCLC patients, 27 of 1,479 (1.8%) had an exon 20 insertion. The median overall survival was 29.4 months (95% confidence interval 9.3 to 49.6) for 27 advanced NSCLC patients. The 22 patients who received systemic CTx achieved a 50.0% response rate and a 77.2% disease control rate, with 4.2 months of progressionfree survival. Six patients received EGFR tyrosine kinase inhibitors (TKIs). Three of the four patients that had only an exon 20 insertion showed progressive disease, while one showed stable disease. The other two patients had an exon 20 insertion and another EGFRmutation and achieved a partial response. Conclusion The incidence of an exon 20 insertion mutation is rare in Korea and occasionally accompanied by other common EGFR mutations. Although the response to systemic CTx. in these patients is comparable to that of patients with other mutations, the response rate to firstor second-generation EGFR TKIs is quite low. Therefore, the development of a more efficient agent is urgently needed.
목차
등록된 정보가 없습니다.
참고문헌 (27)
참고문헌 신청
Torre LA / 2015 / Global cancer statistics, 2012 / CA Cancer J Clin 65:87~108
정규원 / 2017 / Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014 / Cancer Research and Treatment 49(2):292~305
Oser MG / 2015 / Transformation from non-small-cell lung cancer to small-cell lung cancer:molecular drivers and cells of origin / Lancet Oncol 16:e165~e172
Lynch TJ / 2004 / Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib / N Engl J Med 350:2129~2139
Fukui T / 2010 / Successful rechallenge with erlotinib in a patient with EGFRmutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease / Cancer Chemother Pharmacol 65:803~806
정규원 / 2017 / Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014 / Cancer Research and Treatment 49(2):292~305
Oser MG / 2015 / Transformation from non-small-cell lung cancer to small-cell lung cancer:molecular drivers and cells of origin / Lancet Oncol 16:e165~e172
Lynch TJ / 2004 / Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib / N Engl J Med 350:2129~2139
Fukui T / 2010 / Successful rechallenge with erlotinib in a patient with EGFRmutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease / Cancer Chemother Pharmacol 65:803~806
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
Journal of Pathology and Translational Medicine
2015 .01
-
The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Cancer Research and Treatment
2018 .01
-
Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non–Small Cell Lung Cancer: Single-Institution Experience
Cancer Research and Treatment
2024 .07
-
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
Cancer Research and Treatment
2020 .01
-
Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non?small cell lung carcinoma
Journal of Pathology and Translational Medicine
2021 .01
-
Molecular and Clinicopathological Features of Gastrointestinal Stromal Tumors in Vietnamese Patients
Journal of Pathology and Translational Medicine
2019 .01
-
Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
Journal of Pathology and Translational Medicine
2016 .01
-
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer
Cancer Research and Treatment
2022 .01
-
Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology–Based EGFR Mutation Assay in Patients with Operable Non–Small Cell Lung Cancer
Cancer Research and Treatment
2024 .01
-
Prevalence and Clinical Profile of EGFR Mutation In Non-Small-Cell Lung Carcinoma Patients in Southwest China
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing
Yonsei Medical Journal
2018 .01
-
Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer
Cancer Research and Treatment
2015 .01
-
Low-dose Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer is Associated with a High Incidence of Brain Metastasis
Cancer Research and Treatment
2023 .04
-
EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Cancer Research and Treatment
2020 .01
-
Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)
Journal of Pathology and Translational Medicine
2018 .01
-
Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group
Journal of Pathology and Translational Medicine
2019 .01
-
EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
Cancer Research and Treatment
2018 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0